

Astellas Announces Status of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Tokyo, December 1, 2016 – Astellas Pharma Inc. (Tokyo: 4503, President and CEO: Yoshihiko Hatanaka, “the Company”) announced the status of acquisition of its own shares as stated below. The acquisition was implemented pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.

Particulars

- | | |
|--|--|
| 1. Class of shares acquired: | Common stock of the Company |
| 2. Total number of shares acquired: | 21,553,500 shares |
| 3. Aggregate amount of acquisition cost: | 32,808,608,300 yen |
| 4. Date of acquisition: | From November 1, 2016 to November 30, 2016 |
| 5. Method of acquisition: | Purchased on the Tokyo Stock Exchange |

(Reference)

1. Details of the resolution at the meeting of the Board of Directors (announced on October 28, 2016)

- | | |
|--|---|
| - Class of shares to be acquired: | Common stock of the Company |
| - Total number of shares to be acquired: | Up to 30 million shares
(The percentage compared to the total number of shares outstanding: 1.41%) |
| - Aggregate amount of acquisition cost: | Up to 50 billion yen |
| - Period of acquisition: | From October 31, 2016 to December 22, 2016 |

2. Accumulated Company’s own shares acquired through November 30, 2016, pursuant to the above board resolution

- | | |
|---|--------------------|
| - Total number of shares acquired: | 22,682,000 shares |
| - Aggregate amount of acquisition cost: | 34,568,949,600 yen |

#####

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473